Eastern Canadian Colorectal Cancer Consensus Conference 2017

S.F. McGee, W. AlGhareeb, C.H. Ahmad, D. Armstrong, S. Babak, S. Berry, J. Biagi, C. Booth, D. Bossé, P. Champion, B. Colwell, N. Finn, R. Goel, S. Gray, J. Green, M. Harb, A. Hyde, A. Jeyakumar, D. Jonker, S. Kanagaratnam, P. Kavan, A. MacMillan, A. Muinuddin, N. Patil, G. Porter, E. Powell, R. Ramjeesingh, M. Raza, S. Rorke, M. Seal, F. Servidio-Italiano, J. Siddiqui, J. Simms, L. Smithson, S. Snow, E. St-Hilaire, T. Stuckless, A. Tate, M. Tehfe, M. Thirlwell, E. Tsvetkova, M. Valdes, M. Vickers, K. Virik, S. Welch, C. Marginean, T. Asmis


The annual Eastern Canadian Gastrointestinal Cancer Consensus Conference 2017 was held in St. John’s, Newfoundland and Labrador, 28–30 September. Experts in radiation oncology, medical oncology, surgical oncology, and cancer genetics who are involved in the management of patients with gastrointestinal malignancies participated in presentations and discussion sessions for the purpose of developing the recommendations presented here. This consensus statement addresses multiple topics in the management of gastric, rectal, and colon cancer, including

  • identification and management of hereditary gastric and colorectal cancer (crc);
  • palliative systemic therapy for metastatic gastric cancer;
  • optimum duration of preoperative radiation in rectal cancer—that is, short- compared with long-course radiation;
  • management options for peritoneal carcinomatosis in crc;
  • implications of tumour location for treatment and prognosis in crc; and
  • new molecular markers in crc.


Guidelines; gastric cancer; colorectal cancer; rectal cancer; peritoneal carcinomatosis; chemotherapy; radiation therapy; immunotherapy; molecular markers; hereditary cancer syndromes

Full Text:


DOI: http://dx.doi.org/10.3747/co.25.4083

Copyright © 2019 Multimed Inc.
ISSN: 1198-0052 (Print) ISSN: 1718-7729 (Online)